Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Lung Cancer Targeted Therapy

  • Yi-Long Wu
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6829-2


Most cytotoxic drugs for lung cancer are nonselective. They act by damaging cells undergoing mitosis, which is usually more frequent in malignant cells than in most normal cells. Targeted agents are designed to modulate the activity of signal pathways or proteins or enzymes that are necessary and essential for oncogenesis and survival of cancer cells, particularly those driving deregulated growth, angiogenesis, invasion, and metastasis characteristics of malignant cells. The different mechanisms of activity result in lower toxicity for cancer patients, particularly in the bone marrow and in the gastrointestinal tract, and in increased effectiveness. Currently, there are two types of targeting agents in clinical use for the treatment of non-small cell lung cancer (NSCLC): the epidermal growth factor receptor (EGFR), the tyrosine kinase inhibitors (TKIs), and the vascular endothelial growth factor(VEGF) inhibitors. Numerous additional agents targeting other cancer cell...


Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutation Anaplastic Lymphoma Kinase Advanced NSCLC Epidermal Growth Factor Receptor TKIs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521–529CrossRefPubMedGoogle Scholar
  2. Jackman D, Pao W, Riely GJ et al (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28:37–360CrossRefGoogle Scholar
  3. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818CrossRefPubMedGoogle Scholar
  4. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11:121–128CrossRefPubMedGoogle Scholar
  5. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMedGoogle Scholar
  6. National Cancer Institute. NCI dictionary of cancer terms. http://www.cancer.gov/dictionary/
  7. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531CrossRefPubMedGoogle Scholar
  8. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL. J Clin Oncol 27:1227–1234CrossRefPubMedGoogle Scholar
  9. Rosell R, Moran T, Queralt C et al (2009) Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:957–967CrossRefGoogle Scholar
  10. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMedGoogle Scholar
  11. Shepherd FA, Rodrigues PJ, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Guangdong Lung Cancer InstituteGuangdong General Hospital & Guangdong Academy of Medical SciencesGuangzhouChina